Evrys Bio, Inc.
Capital Timeline
Capital this company has received, each line traceable to a primary record. Amounts are obligations, not contract ceilings.
A blank stage means the data is not ingested yet, not that the money stopped there.
Across the lifetime of these contracts, $6.9M has been obligated and $3.5M paid out. $3.4M has not been disbursed.
Cumulative from contract start through 2026-08-17. The total above covers only the transactions ingested in the tracking window — a different measure.
- National Institutes of Health$01
Why It Matters
Not enough signal yet to assess this company's relevance to Japanese firms.
Events
Events used as evidence for Stage / LCI. Facts and interpretation are recorded separately.
EVRYS BIO, INC. — Grant R44AI114079
A SINGLE ANTIVIRAL TO TREAT MULTIPLE OPPORTUNISTIC INFECTIONS - PROJECT SUMMARY/ABSTRACT IMMUNOSUPPRESSED TRANSPLANT PATIENTS HAVE HEIGHTENED SUSCEPTIBILITY TO ENVIRONMENTAL PATHOGENS AS WELL AS ADVENTITIOUS AGENTS TRAVELING WITH DONOR TISSUES OR RESIDENT IN THE RECIPIENT. TRADITIONAL THERAPIES TARGET THE VIRUS AND ARE THEREBY LIMITED IN EFFECTIVENESS TO THE SPECIFIC VIRUS TARGETED. EVRYS BIO IS DEVELOPING ORALLY ADMINISTERED, BROAD-SPECTRUM ANTIVIRALS THAT TARGET THE HOST-CELL SIRTUIN-2 PROTEIN (SIRT2). IN VITRO FEASIBILITY WAS DEMONSTRATED IN SBIR PHASE I FOR AN EARLY LEAD, FLS-359, SHOWING BROAD EFFECTIVENESS AGAINST FOUR FAMILIES OF VIRUSES POSING PROBLEMS FOR IMMUNOSUPPRESSED TRANSPLANT PATIENTS: HERPESVIRUSES, POLYOMAVIRUSES, HEPATITIS VIRUSES, AND RESPIRATORY VIRUSES. ADDITIONALLY, SIRT2-TARGETING WITH FLS-359 BLOCKED ACQUISITION OF VIRAL DRUG RESISTANCE IN AN INFLUENZA MODEL AND WAS ADDITIVE IN ANTIVIRAL ACTIVITY WITH TRADITIONAL DIRECT-ACTING ANTIVIRALS. A PROTOTYPE WAS DEVELO
Timeline
No timeline articles for this company yet.